All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
EMA extends the license indications for rituximab and venetoclax
By Claire Baker
Bookmark this article
The therapeutic potential of two lymphoma therapies has been broadened following the January 2019 European Medicines Agency (EMA) meeting. The EMA has announced license extensions of rituximab and the combination of venetoclax with obinutuzumab.1
The anti-CD20 monoclonal antibody, rituximab, has now been licensed for the treatment of children (≥ six months old) with advanced diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.1
The EMA has also extended the use of venetoclax in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL).1 The combination was approved for this indication by the U.S. Food and Drug Administration (FDA) on May 15, 20192 — read more on the Lymphoma Hub here. The National Institute for Health and Care Excellence (NICE) is currently deciding if the treatment regimen should become available on the NHS.
- Lymphoma-action. More treatment options for DLBCL, Burkitt lymphoma and CLL.https://lymphoma-action.org.uk/more-treatment-options-dlbcl-burkitt-lymphoma-and-cll. Published February 11, 2020 [Accessed February 11, 2020]
- FDA. FDA approves venetoclax for CLL and SLL. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-venetoclax-cll-and-sll. Published May 15, 2019 [Accessed February 11, 2020]
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youNewsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox